IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

FORMULATION AND EVALUATION OF NANOPARTICLES AS CARRIERS OF DAPAGLIFLOZIN FOR ORAL ADMINISTRATION: A REVIEW

Dr.Jyoti Kalra

Department Of Pharmaceutics, School of Pharmaceutical Sciences, Shri Guru Ram Rai University Patel Nagar, Dehradun

Ms.Mitali Gupta, Corresponding Author

Department Of Pharmaceutics, School of Pharmaceutical Sciences, Shri Guru Ram Rai University Patel Nagar, Dehradun

ABSTRACT

Polymeric nanoparticles have emerged as a promising drug delivery system for improving the therapeutic efficacy of pharmaceutical compounds. This review focuses on the formulation, characterization, and evaluation of polymeric nanoparticles as carriers of dapagliflozin for oral administration. Various formulation techniques, including emulsification-solvent evaporation, ionic gelation, nanoprecipitation, and spray drying, have been explored to enhance drug encapsulation efficiency and controlled release. Characterization methods such as particle size analysis, zeta potential, encapsulation efficiency, in-vitro drug release studies, morphological analysis, and Fourier Transform Infrared Spectroscopy (FTIR) play a crucial role in assessing nanoparticle stability and performance. Polymeric nanoparticles offer several pharmacokinetic and therapeutic advantages, including improved bioavailability, sustained drug release, reduced plasma drug fluctuations, and enhanced patient compliance. Despite these advantages, challenges such as large-scale manufacturing, stability concerns, and regulatory hurdles must be addressed. Recent advances in stimuli-responsive nanoparticles, hybrid systems, and surface modifications have further expanded their applicability beyond diabetes management, including cancer therapy, neurological disorders, antimicrobial drug delivery, and vaccine development. This review highlights the potential of polymeric nanoparticles as a transformative drug delivery platform and emphasizes the need for further research to optimize their clinical applications.

Keywords: Polymeric nanoparticles, Dapagliflozin, Drug delivery, Controlled release, Bioavailability, Formulation techniques, Nanomedicine, Diabetes therapy, Targeted drug delivery, Pharmacokinetics

1. INTRODUCTION

Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), is a chronic metabolic disorder characterized by insulin resistance and hyperglycemia. Effective glycemic control is essential to prevent complications such as cardiovascular diseases, nephropathy, and neuropathy. Dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, has gained prominence as an oral anti-diabetic agent due to its insulin-independent mechanism, which enhances urinary glucose excretion. However, its poor aqueous solubility (<10 mg/L) and variable bioavailability (~78%) pose significant challenges to its therapeutic application.

Nanotechnology-based drug delivery systems, particularly polymeric nanoparticles, have shown promise in addressing the limitations associated with poorly water-soluble drugs. Polymeric nanoparticles enhance drug solubility, protect the drug from enzymatic degradation, enable controlled drug release, and improve bioavailability. This review explores the formulation and evaluation of polymeric nanoparticles as carriers for dapagliflozin, highlighting their potential to optimize drug delivery for improved therapeutic outcomes.

2. POLYMERIC NANOPARTICLES: AN OVERVIEW

Polymeric nanoparticles are colloidal carriers composed of biodegradable and biocompatible polymers. They offer several advantages, including:

- Controlled and sustained drug release
- Protection of the encapsulated drug from degradation
- Enhanced bioavailability and targeted drug delivery
- Reduced systemic side effects

Common polymers used for nanoparticle synthesis include poly(lactic-co-glycolic acid) (PLGA), chitosan, polylactic acid (PLA), and polycaprolactone (PCL). These polymers are FDA-approved and widely used in pharmaceutical formulations.

3. FORMULATION TECHNIQUES

Several techniques have been employed for the formulation of polymeric nanoparticles carrying dapagliflozin:

- **Emulsification-Solvent Evaporation:** Involves dissolving the drug and polymer in an organic solvent followed by emulsification and solvent evaporation. This method is widely used for lipophilic drugs and ensures high encapsulation efficiency (Vauthier & Bouchemal, 2009). The size and stability of nanoparticles

can be controlled by optimizing the emulsifier concentration, polymer-to-drug ratio, and solvent removal rate.

- **Ionic Gelation:** Used for hydrophilic polymers like chitosan, allowing the formation of nanoparticles through electrostatic interactions. This technique is simple, mild, and does not require organic solvents (Calvo et al., 1997). The use of crosslinking agents, such as tripolyphosphate (TPP), can improve nanoparticle stability and drug loading efficiency.
- **Nanoprecipitation:** A simple and rapid method where the polymer-drug solution is added to a non-solvent, leading to precipitation of nanoparticles. This technique is particularly useful for hydrophobic drugs and results in small, uniform nanoparticles (Fessi et al., 1989). The rapid diffusion of the solvent into the aqueous phase facilitates controlled particle formation, making it suitable for large-scale production.
- **Spray Drying:** A scalable method involving atomization of polymer-drug solution followed by solvent evaporation. It is suitable for large-scale production and improves the stability of nanoparticles (Vehring, 2008). The choice of excipients and processing parameters, such as inlet temperature and feed rate, significantly affects particle morphology and drug release characteristics.

DRUG PROFILE OF DAPAGLIFLOZIN

Dapagliflozin is an oral antidiabetic drug belonging to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It has the molecular formula $C_{21}H_{25}ClO_6$ and a molecular weight of 408.88 g/mol**.** The drug works by selectively inhibiting **SGLT2** in the proximal tubules of the kidneys, reducing glucose reabsorption and promoting glucose excretion through urine, thereby lowering blood glucose levels. Dapagliflozin has a bioavailability of approximately 78% and a half-life of 12.9 hours**,** with metabolism primarily occurring in the liver via the UGT1A9 enzyme**.** The drug is excreted mainly through urine (**~75%**) and feces (**~21%**). Despite its efficacy, dapagliflozin has limitations such as poor aqueous solubility**,** which affects its absorption, and potential side effects like an increased risk of urinary tract infections and renal complications with prolonged use.

Formulating dapagliflozin using polymeric nanoparticles offers several advantages. Polymeric carriers such as PLGA, chitosan, and PCL improve the drug's solubility, enhance bioavailability**,** and enable controlled release**,** reducing the need for frequent dosing. Additionally, nanoparticle-based delivery can help minimize plasma concentration fluctuations, lowering the risk of adverse effects. Future research focuses on developing targeted nanoparticle formulations that deliver dapagliflozin directly to the kidneys, improving therapeutic efficacy while minimizing systemic exposure.

4. CHARACTERIZATION OF POLYMERIC NANOPARTICLES

To ensure optimal drug delivery performance, polymeric nanoparticles undergo thorough characterization, including:

- **Particle Size and Zeta Potential:** Particle size influences the bioavailability and cellular uptake of nanoparticles. Smaller particles (<200 nm) enhance permeability and absorption, while larger particles may face challenges in crossing biological barriers. Zeta potential determines colloidal stability, with values above ±30 mV indicating strong repulsion between particles, reducing aggregation and improving dispersion stability.
- **Encapsulation Efficiency (EE) and Drug Loading (DL):** Encapsulation efficiency measures the percentage of dapagliflozin successfully encapsulated within the nanoparticles, while drug loading quantifies the amount of drug relative to the total nanoparticle weight. High EE and DL are crucial for effective drug delivery, as they ensure maximum therapeutic benefit with minimal excipients.
- **In-vitro Drug Release Studies:** Drug release studies assess the kinetics of dapagliflozin release from polymeric nanoparticles under simulated physiological conditions. Controlled and sustained release profiles can be analyzed using models such as Higuchi, Korsmeyer-Peppas, and zero-order kinetics to understand the release mechanisms (diffusion, erosion, or swelling).
- **Morphological Analysis (SEM/TEM):** Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) provide insights into the shape, surface morphology, and structural integrity of nanoparticles. Spherical and uniform nanoparticles are generally preferred for efficient drug delivery.
- **Fourier Transform Infrared Spectroscopy (FTIR):** FTIR analysis detects chemical interactions between dapagliflozin and the polymer matrix. It helps confirm the successful encapsulation of the drug and ensures that no significant chemical modifications or degradation occur during formulation.

5. PHARMACOKINETIC AND THERAPEUTIC ADVANTAGES

Polymeric nanoparticles improve the pharmacokinetic profile of dapagliflozin by:

- **Enhancing Bioavailability:** Poorly water-soluble drugs like dapagliflozin benefit from nanoparticle encapsulation, which increases surface area, dissolution rate, and intestinal permeability, leading to improved absorption.
- **Providing Controlled and Sustained Drug Release:** Polymeric nanoparticles enable prolonged drug release, reducing dosing frequency and enhancing patient compliance. Controlled release minimizes rapid fluctuations in drug levels, ensuring a steady therapeutic effect.
- **Reducing Fluctuations in Plasma Drug Concentrations:** Conventional formulations often lead to peaks and troughs in drug levels, increasing the risk of side effects such as dehydration and hypotension. Nanoparticles stabilize plasma concentrations, improving drug efficacy and safety.
- **Targeted Drug Delivery:** Functionalized nanoparticles with ligands (e.g., folic acid, transferrin) can target specific tissues or cells, enhancing therapeutic action while reducing systemic toxicity.

- **Potential Dose Reduction:** Improved bioavailability and targeted delivery may allow for lower drug doses while maintaining therapeutic efficacy, reducing the risk of adverse effects and treatment costs.

6. CHALLENGES AND FUTURE PERSPECTIVES

Despite their advantages, polymeric nanoparticles face several challenges that must be addressed for successful clinical translation:

- **Scale-up and Reproducibility Issues:** Large-scale manufacturing of polymeric nanoparticles while maintaining uniformity in size, drug loading, and release profiles remains a significant challenge. Optimizing formulation parameters and developing scalable, cost-effective production methods are essential.
- **Stability Concerns:** Storage and transport conditions can impact nanoparticle stability, leading to aggregation, drug leakage, or polymer degradation. Lyophilization (freeze-drying) and the use of cryoprotectants are potential solutions to enhance long-term stability.
- **Potential Cytotoxicity and Biocompatibility:** Some synthetic polymers may pose cytotoxicity risks or elicit immune responses. Careful selection of biocompatible and biodegradable polymers, along with extensive in-vitro and in-vivo safety evaluations, is necessary to ensure patient safety.
- **Regulatory and Approval Challenges:** Nanoparticle-based drug delivery systems require extensive preclinical and clinical evaluations to meet regulatory standards for safety and efficacy. Standardized protocols for characterization and testing are needed to facilitate regulatory approvals.
- **Future Perspectives:** Advances in polymer engineering, targeted drug delivery strategies, and personalized medicine can further enhance the potential of polymeric nanoparticles. Integrating stimuli-responsive and smart nanocarriers capable of responding to physiological conditions (e.g., pH-sensitive, enzyme-triggered release) could revolutionize oral drug delivery for dapagliflozin and other therapeutics.

Continued research efforts should focus on overcoming these challenges through interdisciplinary collaboration, innovative formulation techniques, and clinical validation to ensure the successful translation of polymeric nanoparticle-based therapies into clinical practice.

7. RECENT ADVANCES IN POLYMERIC NANOPARTICLES FOR DRUG DELIVERY

The field of polymeric nanoparticles has witnessed several innovations that enhance drug delivery efficacy:

- **Stimuli-Responsive Nanoparticles:** Smart nanoparticles that respond to environmental triggers such as pH, temperature, or enzymes have been developed to achieve site-specific drug release. For example, pH-sensitive nanoparticles release drugs in the acidic tumor microenvironment or inflamed tissues, minimizing systemic exposure and enhancing therapeutic outcomes. Enzyme-responsive nanoparticles can be activated by specific biological enzymes, allowing precise control over drug release at the target site.
- **Hybrid Nanoparticles:** Combining polymeric nanoparticles with other nanocarriers, such as liposomes, dendrimers, or inorganic nanoparticles (gold, silica), enhances stability and provides multifunctional drug

delivery systems. Hybrid nanoparticles improve drug loading capacity, increase circulation time, and enable dual or multi-drug delivery, making them suitable for complex diseases requiring combination therapies.

- **3D Printing of Nanoparticles:** The use of 3D printing technology for the fabrication of polymeric nanoparticles allows precise control over particle size, shape, and drug release kinetics, optimizing therapeutic efficacy. This technique enables the production of patient-specific drug formulations with tailored release profiles, offering a step towards personalized medicine.
- **Surface-Modified Nanoparticles:** Functionalization of nanoparticles with polyethylene glycol (PEG), antibodies, peptides, or aptamers enables targeted drug delivery and prolongs circulation time in the bloodstream. PEGylation enhances nanoparticle stability by reducing opsonization and clearance by the immune system, improving bioavailability. Targeting ligands, such as folic acid or transferrin, facilitate receptor-mediated uptake by specific cells, improving drug accumulation at the disease site.

8. Applications Beyond Diabetes Therapy Although primarily explored for dapagliflozin delivery in diabetes management, polymeric nanoparticles hold promise for broader applications in various therapeutic fields:

- **Cancer Therapy:** Nanoparticles enable targeted delivery of chemotherapeutic agents, reducing systemic toxicity and enhancing efficacy. Nanoparticles can passively accumulate in tumor tissues via the enhanced permeability and retention (EPR) effect or actively target cancer cells using surface-modified ligands. Encapsulation of anticancer drugs such as doxorubicin and paclitaxel in polymeric nanoparticles has demonstrated improved therapeutic effects with reduced side effects.
- **Neurological Disorders:** Polymeric nanoparticles facilitate drug transport across the blood-brain barrier (BBB), offering potential treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Conventional drugs for these diseases often struggle with poor BBB permeability, but nanoparticles can be engineered with surface modifications (e.g., transferrin receptors, cell-penetrating peptides) to enhance brain targeting. Drug-loaded nanoparticles can deliver neuroprotective agents, anti-inflammatory drugs, and gene therapies with improved bioavailability and prolonged effects.

- **Antimicrobial Drug Delivery:** Nanoparticles improve the bioavailability of antibiotics and antimicrobial agents, overcoming issues like bacterial resistance. Encapsulation of antibiotics within polymeric nanoparticles protects them from enzymatic degradation, enhances penetration into bacterial biofilms, and enables controlled release to maintain therapeutic drug levels. Nanoparticle-based drug carriers have shown promising results against multidrug-resistant bacterial strains.
- **Vaccine Development:** Polymeric nanoparticles serve as antigen carriers, enhancing immune response and vaccine stability. Nanoparticles can protect antigenic proteins from degradation, facilitate controlled antigen release, and act as adjuvants to boost immuneresponses. Nanoparticle-based vaccines, such as those for COVID-19, have demonstrated significant advantages in terms of stability, immunogenicity, and targeted delivery to immune cells.

CONCLUSION

Polymeric nanoparticles represent a promising approach for enhancing the solubility, bioavailability, and therapeutic efficacy of dapagliflozin. Their ability to provide controlled and sustained drug release, protect drugs from degradation, and enable targeted delivery offers significant advantages over conventional drug formulations. Advances in polymer engineering, stimuli-responsive systems, and surface modifications further expand their potential in personalized medicine and complex disease management.

Despite these advantages, several challenges remain, including large-scale manufacturing, stability concerns, regulatory hurdles, and potential toxicity issues. Addressing these challenges through interdisciplinary research, novel formulation strategies, and rigorous clinical evaluations will be crucial for the successful translation of polymeric nanoparticle-based drug delivery systems into clinical practice.

Beyond diabetes therapy, polymeric nanoparticles hold immense potential in oncology, neurology, antimicrobial therapy, and vaccine development. Continued research and innovation in nanotechnology can pave the way for more effective and patient-centric treatment approaches.

In conclusion, polymeric nanoparticles offer a transformative approach to drug delivery, with the potential to revolutionize pharmacotherapy across multiple therapeutic areas. Their continued development and optimization will be essential in achieving safer, more effective, and targeted treatments for a wide range of diseases.

REFERENCES

1. Vauthier, C., & Bouchemal, K. (2009). Methods for the preparation and manufacture of polymeric nanoparticles. *Pharmaceutical Research, 26*(5), 1025-1058. https://doi.org/10.1007/s11095-008-9800-3

2. Calvo, P., Remuñán-López, C., Vila-Jato, J. L., & Alonso, M. J. (1997). Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. *Journal of Applied Polymer Science, 63*(1), 125-132. https://doi.org/10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4

3. Fessi, H., Puisieux, F., Devissaguet, J. P., Ammoury, N., & Benita, S. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. *International Journal of Pharmaceutics, 55*(1), R1-R4. https://doi.org/10.1016/0378-5173(89)90281-0

4. Vehring, R. (2008). Pharmaceutical particle engineering via spray drying. *Pharmaceutical Research, 25*(5), 999-1022. https://doi.org/10.1007/s11095-007-9475-1

5. Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids and Surfaces B: Biointerfaces, 75*(1), 1-18. https://doi.org/10.1016/j.colsurfb.2009.09.001

6. Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016). Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. *Chemical Reviews, 116*(4), 2602-2663. https://doi.org/10.1021/acs.chemrev.5b00346

7. Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Molecular Pharmaceutics, 5*(4), 505-515. https://doi.org/10.1021/mp800051m

8. Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nature Reviews Drug Discovery, 13*(11), 813-827. https://doi.org/10.1038/nrd4333

9. Zhang, L., Chan, J. M., Gu, F. X., Rhee, J. W., Wang, A. Z., Radovic-Moreno, A. F., & Langer, R. (2008). Self-assembled lipid−polymer hybrid nanoparticles: A robust drug delivery platform. *ACS Nano, 2*(8), 1696-1702. https://doi.org/10.1021/nn800275r

10. Panyam, J., & Labhasetwar, V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. *Advanced Drug Delivery Reviews, 55*(3), 329-347. https://doi.org/10.1016/S0169-409X(02)00228-4

11. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. *Journal of Controlled Release, 161*(2), 505-522. https://doi.org/10.1016/j.jconrel.2012.01.043

12. Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. *Polymers, 3*(3), 1377-1397. https://doi.org/10.3390/polym3031377

13. Mundargi, R. C., Babu, V. R., Rangaswamy, V., Patel, P., & Aminabhavi, T. M. (2008). Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. *Journal of Controlled Release, 125*(3), 193-209. https://doi.org/10.1016/j.jconrel.2007.09.013

14. Park, K. (2017). Facing the truth about nanotechnology in drug delivery. *ACS Nano, 11*(3), 2392-2397. https://doi.org/10.1021/acsnano.7b01445

15. Pandey, A., Jain, D. S., Chakraborty, S., & Jain, R. (2021). Polymeric nanocarriers: A review on drug delivery system. *Journal of Drug Delivery Science and Technology, 61*, 102114. https://doi.org/10.1016/j.jddst.2021.102114